Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2026-04-20 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
2025年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025. The content includes detailed descriptions of internal control scope, defect identification standards, and remediation status. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document is about internal control evaluation, which aligns with the category of Audit Report / Information (AR), as it is a standalone audit-related report on internal controls and does not contain full financial statements or annual report content. The document length is 4009 characters, which is sufficient for a detailed report and not a mere announcement. Therefore, the best classification is AR with high confidence. FY 2025
2026-04-20 Chinese
关于公司名称变更完成工商登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Obio Technology (Group) Corp., Ltd. regarding the completion of the company name change registration and issuance of a new business license. It details the updated company name, registration code, capital, legal representative, and business scope. There is no financial data, report, or detailed analysis present. The document is a formal regulatory announcement about corporate registration changes, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-03-02 Chinese
关于参与设立产业投资基金进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Heyuan Biotechnology (Group) Co., Ltd. regarding the progress of its participation in establishing an industrial investment fund. It details the investment amount, changes in the fund's capital, and the impact on the company. The document includes specific dates, investment details, and references to previous announcements but does not contain financial statements or comprehensive financial analysis. The length is 2568 characters, which is relatively short and typical for an announcement rather than a full report. The content focuses on investment progress and fund capital changes, which aligns with updates on financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-03-02 Chinese
2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025 年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, and other financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the 2025 Annual Report. The document is relatively short (2359 characters) and serves as a quick earnings update rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of report publication but a brief financial performance summary. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2025
2026-02-26 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2026 first extraordinary shareholders' meeting of Heyuan Bio-Technology (Shanghai) Co., Ltd. It includes details about the meeting date, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is relatively short (2058 characters), and it serves as an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-02-26 Chinese
关于和元生物技术（上海）股份有限公司2026年第一次临时股东会之法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and validity of an extraordinary shareholders’ meeting (临时股东会). It is not a management discussion or earnings release, nor is it a proxy solicitation or detailed financial report. It is also not a director dealing, M&A announcement, or dividend notice. It serves as a compliance/legal document filed with the stock exchange. Therefore, it falls into the general “Regulatory Filings” category as it does not match any more specific filing type.
2026-02-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.